<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药投资并购俱乐部 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-06T20:27:14+08:00</updated>
  <subtitle>healthib俱乐部是医药医疗健康领域企业家与投资人的资源共享与价值共创的非营利性公众学习平台，专注于投资并购与产业整合资源的分享和学习，感谢您的关注！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>曲伏前列素——打破垄断的进程</title>
    <updated>2020-10-26T16:03:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/7xAaW_CGunoDU6sQqTJtHQ</id>
    <link href="https://mp.weixin.qq.com/s/7xAaW_CGunoDU6sQqTJtHQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Gilteritinib-复发性/难治性FLT3突变的急性髓系白血病新标准疗法</title>
    <updated>2020-10-23T16:00:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/s4dp8hni4k5nrV5gLqAG4g</id>
    <link href="https://mp.weixin.qq.com/s/s4dp8hni4k5nrV5gLqAG4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Midostaurin-首个获批的FLT3抑制剂用于治疗急性髓系白血病</title>
    <updated>2020-10-22T14:57:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/1exIrBQk0DgmOnJK8PYo9g</id>
    <link href="https://mp.weixin.qq.com/s/1exIrBQk0DgmOnJK8PYo9g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>急性髓系白血病中的FLT-3突变</title>
    <updated>2020-10-21T15:56:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-21:/s/4Oi0Tj7fxLCRme6R3HnUEg</id>
    <link href="https://mp.weixin.qq.com/s/4Oi0Tj7fxLCRme6R3HnUEg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>含聚季铵盐-1防腐剂的0.004％曲伏前列素滴眼液于青光眼的小儿患者的药代动力学和安全性研究</title>
    <updated>2020-10-20T15:14:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-20:/s/5sa9gU6ZO0vHNH9bwlj5Kw</id>
    <link href="https://mp.weixin.qq.com/s/5sa9gU6ZO0vHNH9bwlj5Kw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>小儿青光眼或高眼压症患者使用噻吗洛尔与0.004％曲伏前列素眼药水进行3个月安全性和有效性对比研究</title>
    <updated>2020-10-19T13:55:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-19:/s/S-4vU9xsdQjf0jPxYgQt1w</id>
    <link href="https://mp.weixin.qq.com/s/S-4vU9xsdQjf0jPxYgQt1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拉坦前列素的近期研究（下）</title>
    <updated>2020-10-15T16:41:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/U7vvLDiUXlmpn0EPwKPhlQ</id>
    <link href="https://mp.weixin.qq.com/s/U7vvLDiUXlmpn0EPwKPhlQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拉坦前列素的近期研究</title>
    <updated>2020-10-13T15:57:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-13:/s/fCtT2NKuptq87FmnaLj2JQ</id>
    <link href="https://mp.weixin.qq.com/s/fCtT2NKuptq87FmnaLj2JQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>角膜生物力学修正修饰的戈德曼棱镜证明了拉坦前列素0.005％的局部疗效</title>
    <updated>2020-10-12T17:03:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-12:/s/NquykOBYjNc9ObywhSGC3Q</id>
    <link href="https://mp.weixin.qq.com/s/NquykOBYjNc9ObywhSGC3Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>大剂量拉坦前列素治疗葡萄膜炎引起的难治性眼功能低下</title>
    <updated>2020-10-10T16:12:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-10:/s/TgkdFY0vjdWUDntltxVzKQ</id>
    <link href="https://mp.weixin.qq.com/s/TgkdFY0vjdWUDntltxVzKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>